Lymphotropic nanoparticle enhanced MR imaging (LNMRI) technique for lymph node imaging.
Accurate nodal staging is important in the management of any primary malignancy. The presence of nodal metastases has both therapeutic and prognostic implications. Lymphotropic nanoparticles are a new class of MRI contrast agents, which are promising in detecting minimal metastatic nodal disease particularly in normal sized lymph nodes. This paper discusses the technique and interpretation of lymphotropic nanoparticle enhanced MRI (LNMRI) and reviews the various trials evaluating nodal staging with ferumoxtran-10 enhanced MRI.
Center for Molecular Imaging Research, Building 149, 13th Street, Room 5406, Charlestown, MA 02129-2060, USA.
Mansi A
MA
Saksena
Anuradha
A
Saokar
Mukesh G
MG
Harisinghani
D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects; D003911:Dextrans; D052203:Ferrosoferric Oxide; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D007501:Iron / Q000009:adverse effects; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008279:Magnetic Resonance Imaging / Q000379:methods*; D058185:Magnetite Nanoparticles; D008488:Medical Illustration; D049329:Nanostructures / Q000009:adverse effects; D009367:Neoplasm Staging; D010087:Oxides / Q000009:adverse effects; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; C097921:ferumoxtran-10; D007501:Iron; D052203:Ferrosoferric Oxide